Sponsored by:

Molecular Imaging

Ratio Therapeutics, RayzeBio join forces
By AuntMinnie.com staff writers
The firms will collaborate on a radiopharmaceutical program focused on two cancer targets.
September 9, 2026
Hands Shaking Deal
Coalition launches Cardiac PET Alliance
By AuntMinnie.com staff writers
The coalition represents more than 1,200 cardiologists across 101 cardiovascular group practices in 24 states.
September 9, 2026
Heart Valves Artx Premium
Siemens expands PET detector manufacturing site
By AuntMinnie.com staff writers
The project significantly increases production capacity at its East Tennessee Molecular Imaging Complex.
September 9, 2026
Siemens Pet Manufacturing Center
GEHC submits StarGuide GX digital SPECT/CT for FDA clearance
By AuntMinnie.com staff writers
The system uses dual-sided cadmium zinc telluride (CZT) detector technology for higher volume sensitivity and high-res imaging.
September 8, 2026
Ge Health Care Standard Logo
AtomVie opens new radiopharmaceutical manufacturing facility
By AuntMinnie.com staff writers
The new site increases the firm's manufacturing capacity by more than tenfold.
September 4, 2026
Isotope 400
Juniper secures FDA 'breakthrough' nod for hypoxia PET tracer
By AuntMinnie.com staff writers
JBS-003, licensed from Memorial Sloan Kettering Cancer Center, identifies tumor hypoxia, a marker of radioresistance.
September 3, 2026
Throat Cancer
Telix completes enrollment in BiPASS study
By AuntMinnie.com staff writers
In earlier studies, combining Ga-68 PSMA-PET with MRI reduced unnecessary biopsies by nearly 50 percent.
September 2, 2026
Prostate Imaging
Ionetix begins shipping At-211 in North America
By AuntMinnie.com staff writers
Alpha emitters like At-211 deliver high-energy radiation over a very short range.
September 2, 2026
Nuclear Medicine
SPECT/CT access unequal across U.S.
By Will Morton
At the state level, California, Texas, and Florida had the highest number of facilities in absolute terms.
September 1, 2026
Shutterstock 2028051956 (1)
Bayer's PET agent meets endpoints in phase III cardiac amyloidosis study
By Will Morton
Overall sensitivity was 94% (95% CI, 85% to 98%) and specificity was 86% (95% CI, 77% to 92%).
August 31, 2026
This figure shows fused I-124 evuzamitide positron emission tomography (PET)/computed tomography (CT) images from patients without amyloidosis and from patients with ATTR cardiac amyloidosis, early ATTR cardiac amyloidosis, light chain cardiac amyloidosis, gelsolin-mediated amyloidosis, and systemic organ amyloid. The columns represent radiological transaxial, sagittal, and coronal views except for the last row middle and far right columns, which are coronal projections. The blue asterisks represent physiological activity (tracer activity in the stomach and esophagus). The arrowheads represent pathological uptake. Note the small amount of cardiac uptake in the basal septum and the basal lateral walls (likely early ATTR cardiac amyloidosis), splenic uptake and pleural uptake in light chain amyloidosis, and cardiac and kidney uptake in gelsolin-mediated amyloidosis. The bright yellow color represents more tracer uptake.
PET outperforms CT in ovarian cancer
By Will Morton
Peritoneal carcinomatosis in ovarian cancer is cancer that has spread from the ovaries to the peritoneum.
August 28, 2026
Comparison of contrast-enhanced CT (ceCT) and FAPI-PET in detecting peritoneal carcinomatosis in patient with advanced ovarian carcinoma. (A) ceCT shows subtle peritoneal thickening that is difficult to delineate. (B) Maximum-intensity-projection image demonstrating diffuse intense FAPI uptake corresponding to extensive peritoneal carcinomatosis. (C) FAPI-PET shows intense uptake corresponding with peritoneal carcinomatosis, with improved lesion conspicuity over ceCT.
PET/CT outperforms MRI after focal therapy for prostate cancer
By Will Morton
No accurate noninvasive method has been validated to evaluate treatment response after focal therapy.
August 20, 2026
True-positive PSMA-PET with positive MRI in 74-year-old male with prostate cancer (Gleason score of 4 + 5; left anterior and posterior apex positive cores). (A) Left posterior peripheral apical to midprostate hyposignal visible on transaxial MRI. (B) No definite CT correlate evident (white arrow). (C) Focal high PSMA expression detectable in left posterior mid to base with SUVmax of 12.4 on transaxial fused delayed pelvic PET/CT (yellow arrow). (D) Focal high PSMA expression found in left midgland to base of prostate on maximum-intensity-projection image (yellow arrow).
Page 1 of 634
Next Page